Walmart, Inc | Health Data Privacy Assessment at Walmart, Inc

Status
Filed
Previous AGM date
Resolution details
Company ticker
WMT
Lead filer
AFL-CIO Reserve Fund
Resolution ask
Report on or disclose
ESG theme
  • Social
ESG sub-theme
  • Public health
Type of vote
Shareholder proposal
Filer type
Shareholder
Company sector
Consumer Discretionary
Company HQ country
United States
Resolved clause
RESOLVED: Shareholders request the Board of Directors of Walmart Inc. (the ?Company?) commission an independent, third-party assessment of the Company?s policies regarding law enforcement information requests relating to the use of medications by the Company?s customers and employees. The assessment, prepared at reasonable cost and omitting legally privileged, confidential, or proprietary information, should be publicly disclosed on the Company?s website.
Supporting statement
RESOLVED: Shareholders request the Board of Directors of Walmart Inc. (the ?Company?) commission an independent, third-party assessment of the Company?s policies regarding law enforcement information requests relating to the use of medications by the Company?s customers and employees. The assessment, prepared at reasonable cost and omitting legally privileged, confidential, or proprietary information, should be publicly disclosed on the Company?s website. SUPPORTING STATEMENT: Federal and state laws regarding the sale and distribution of medication may conflict or have contested application. For example, a conflict of laws may arise regarding certain medications related to contraception, abortion, and gender-affirming treatments. While our Company is not exempt from law enforcement requests related to these medications, we believe that our Company can enhance trust with its customers and employees by adopting and disclosing robust data privacy and data collection minimization practices. For these reasons, we believe that an independent, third-party assessment of the Company?s policies regarding law enforcement information requests relating to the Company?s customers and employees use of medications would be beneficial for the Board of Directors in the exercise of its fiduciary duties. In addition, disclosing the results of the assessment will provide greater transparency for the Company?s shareholders, customers, and employees. For these reasons, we urge you to vote FOR this proposal.

DISCLAIMER: By including a shareholder resolution or management proposal in this database, neither the PRI nor the sponsor of the resolution or proposal is seeking authority to act as proxy for any shareholder; shareholders should vote their proxies in accordance with their own policies and requirements.

Any voting recommendations set forth in the descriptions of the resolutions and management proposals included in this database are made by the sponsors of those resolutions and proposals, and do not represent the views of the PRI.

Information on the shareholder resolutions, management proposals and votes in this database have been obtained from sources that are believed to be reliable, but the PRI does not represent that it is accurate, complete, or up-to-date, including information relating to resolutions and management proposals, other signatories’ vote pre-declarations (including voting rationales), or the current status of a resolution or proposal. You should consult companies’ proxy statements for complete information on all matters to be voted on at a meeting.